Latest news with #ImmunoPrecise
National Post
2 days ago
- Business
- National Post
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
Article content LENS ai ™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENS ai ™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. This discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the Company's newly launched, HYFT pattern-patented AI-native vaccine discovery engine. Article content Dr. Jennifer Bath, ImmunoPrecise Antibodies CEO commented, 'This breakthrough highlights a new frontier in AI-driven biology—where discovery is rooted in the biology of a virus itself. By confirming that our sequence-derived patented HYFT patterns match structural signatures across all dengue serotypes, we're setting the stage for a universal vaccine design framework. Ultimately, this research validates a persistent target that may allow doctors to home in on a signal to eliminate the virus regardless of mutations that may have occurred. More importantly, the implications appear to stretch far beyond the dengue virus. This is a foundation that research indicates can now be applied to many other infectious diseases and potentially even certain types of cancer.' Article content Building on this success in dengue, IPA now intends to extend its AI-driven vaccine design platform to other high-impact infectious diseases, for example, HIV, Norovirus, and an improved RSV vaccine. Early-stage assessments are also underway to explore the platform's application in oncology for neoantigen vaccine development and tumor-specific epitope mapping. Article content This discovery underscores IPA's commitment to advancing drug discovery through innovative, human-relevant AI technologies that align with evolving industry standards. Using HYFT's patented ability to map biologically meaningful sub-sequence patterns across the entire biosphere, the Company's proprietary LENS ai platform identified a unique epitope shared across all four serotypes of the dengue virus—DENV-1, DENV-2, DENV-3, and DENV-4. These serotypes are distinct versions of the virus that circulate globally, and because infection with one does not protect against the others, identifying a common target is a critical step toward developing a broadly protective dengue vaccine. Unlike traditional trial-and-error methods, IPA's discovery was achieved entirely in silico, demonstrating the platform's power to translate complex biological data into actionable vaccine design. Article content Why Has a Universal Dengue Vaccine Been So Elusive? Article content Dengue is not just one virus—it's four distinct, rapidly-evolving serotypes. Immunity to one does not guarantee protection from the others, and prior infection can even make subsequent disease worse. For decades, vaccine researchers have struggled to find a viral component that is both exposed and truly conserved across all four types—a challenge compounded by the virus's rapid mutation and complex immune interactions. Traditional methods, whether experimental or computational, have repeatedly fallen short, unable to fully bridge the gap between sequence, structure, and function at a meaningful scale. Article content Confirmed Breakthrough: Sequence and Structural HYFT Match Across All Four Serotypes Article content IPA's discovery is a landmark moment in computational vaccinology. Using its proprietary LENSai™ platform powered by their patented HYFT® technology, the company has identified a strictly conserved epitope across all four dengue virus serotypes— a viral signature that remains unchanged despite mutations and serotype variation, and that can be targeted to trigger the immune system in efforts to eliminate the virus. This achievement marks a critical milestone in the quest for a universal dengue vaccine. Article content What sets this apart is the depth of validation: Article content Patented HYFT patterns, derived based on the conservation of sequence data. were independently confirmed to match corresponding structural HYFTs across all four dengue serotypes. This was made possible through LENS ai 's integration of over 20 million proprietary Structural HYFTs (S-HYFTs), enabling the platform to overlay three-dimensional conformations onto sequence-level, biology-native fingerprints. The validation demonstrates that LENS ai doesn't simply identify linear motifs—it can infer conformational and functional structures from sequence data alone, bypassing the need for time-consuming experimental techniques like crystallography or cryo-EM. Article content This milestone affirms the patented HYFT technology's unique ability to traverse the full biological hierarchy—from DNA/RNA sequence to molecular structure to therapeutic relevance. It signals that AI-native models, rooted in biology-first principles, can now deliver actionable insights previously achievable only through years of wet-lab research. Article content The end-to-end LENS ai platform integrates patented HYFT® universal fingerprints with deep learning, structural predictions, and literature-mined knowledge graphs to rapidly identify and refine candidate epitopes—without requiring lab-based inputs. The result: full immunogen design and in silico immunogenicity screening, dramatically reducing the time and cost of early-stage vaccine development and unlocking new opportunities to tackle even the most complex viral challenges. Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, adoption, and broader application of the LENS ai ™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery and vaccine development methods; the expansion of IPA's discovery engine to additional infectious disease and oncology targets; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum. Article content Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance, competitive or market dynamics, intellectual property protection and enforcement, integration or operational risks, and changes in economic or business conditions. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Article content Article content Article content Article content
National Post
21-05-2025
- Business
- National Post
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. Article content Article content CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audiences. Article content 'This collaboration with CORE IR represents an important step in IPA's ongoing commitment to improving our communication with the investment community and increasing market visibility,' said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. 'As we continue to execute on our growth strategy and expand our global capabilities, we believe CORE IR's expertise will help us better articulate our value proposition to existing and prospective shareholders.' Article content Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, investor outreach, and support for IPA's communication programs. Article content 'We are excited to work alongside the team at IPA,' said Scott Gordon, Co-Founder and President of CORE IR. 'IPA has established itself as a pioneering force in the antibody discovery and development space. We look forward to helping the company increase its engagement with the broader investment community.' Article content ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). For more information, visit Article content Article content Article content Article content Contacts Article content Investor Relations Louie Toma, CPA, CFA Managing Director Article content Article content Article content
National Post
20-05-2025
- Business
- National Post
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference
Article content Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be presenting at the Maxim Group's virtual conference: Article content The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT, business solutions, gaming & entertainment, and more. In Maxim's 2025 Virtual Tech Conference, we will explore how emerging growth companies are expanding their use of Quantum Computing and Artificial Intelligence (AI) to position themselves for the future. Maxim Senior Analysts will facilitate engaging dialogues with CEOs and key management of diverse companies who have their attention on technology and how it will impact and grow their business. Article content This conference will be live on M-Vest. To attend, sign up to become an M-Vest member in the above registration link. Article content About Maxim Group LLC Article content Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit Article content ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). Article content Article content Article content Article content Contacts Article content Article content Article content
National Post
12-05-2025
- Business
- National Post
IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENS ai ™ platform, with a direct comparison to gold-standard wet-lab methods. Article content Article content The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENS ai 's AI-powered platform was able to match the performance of x-ray crystallography—the industry's most precise but slowest and most expensive method—using sequence data alone. Article content 'In an industry where over 95% of drug candidates fail before reaching the clinic, accelerating decisions earlier in the discovery pipeline isn't a luxury—it's a necessity,' said Dr. Jennifer Bath, CEO of IPA. 'With LENS ai, we're demonstrating that AI is designed to deliver accurate, scalable, and human-relevant biological predictions that were previously only accessible through months of experimental work.' Article content In the benchmarking study, LENS ai 's in silico epitope mapping application was tested across five known antibody-antigen pairs and against multiple experimental techniques, including HDX-MS, alanine scanning, and x-ray crystallography. The AI system produced predictive scores (AUC 0.79–0.89) comparable to or exceeding those achieved by leading wet-lab methods, while reducing turnaround time from weeks to hours. Article content Epitope mapping is a cornerstone of antibody development, informing everything from IP strategy to candidate selection. Traditionally, this requires expensive, time-consuming lab work using scarce protein samples. LENS ai transforms this by delivering early-stage epitope insights from sequence alone, reducing both cost and risk. Article content This breakthrough aligns with growing regulatory and industry momentum around New Approach Methodologies (NAMs), including the FDA's recent decision to phase out animal testing requirements for biologics. By eliminating the need for physical materials and enabling near–x-ray-level precision, LENS ai advances ethical, scalable, and high-resolution approaches to biotherapeutic discovery Article content We view this achievement as a meaningful advancement that enhances the capabilities of drug discovery platforms' added Dr. Bath. 'LENS ai is now capable of providing pharma and biotech partners with validated, in silico answers to questions that once required months of wet-lab commitment.' Article content This latest achievement marks a major step in the broader development of LENS ai, IPA's AI-driven discovery platform. Building on previous releases, including in silico antibody engineering, epitope prediction, and multi-omics integration, LENS ai continues to demonstrate its ability to deliver high-resolution, scalable insights across key stages of biotherapeutic discovery. Today's advancement in epitope mapping reflects the growing power of the platform we have been strategically building — connecting sequence-based precision, accelerated timelines, and deep scientific insight to transform the future of therapeutic development. Article content ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements often include words such as 'expects,' 'intends,' 'anticipates,' 'believes,' or variations thereof, or state that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur. These statements relate to, among other things, the anticipated benefits, scalability, and adoption of the LENSai platform, the broader application of HYFT®-based tools, the advancement of AI-native drug discovery methods, and the Company's ability to maintain regulatory alignment and commercial traction. Article content Although the Company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors largely beyond the Company's control, including but not limited to scientific and technological developments, regulatory changes and acceptance, competitive dynamics, IP protection, platform integration challenges, and financial and operational risks. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information on risks and uncertainties can be found in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly. Article content Article content Article content Article content Article content Article content
